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Abstract 28 
Background 29 
Gene therapy is a promising approach with enormous potential for treatment of 30 
neurodegenerative disorders. Viral vectors derived from canine adenovirus type 2 31 
(CAV-2) present attractive features for gene delivery strategies in the human brain, by 32 
preferentially transducing neurons, are capable of efficient axonal transport to afferent 33 
brain structures, have a 30-kb cloning capacity and have low innate and induced 34 
immunogenicity in humans. For clinical translation, in-depth pre-clinical evaluation of 35 
efficacy and safety in a human setting is primordial. Stem cell-derived human neural 36 
cells have a great potential as complementary tools by bridging the gap between animal 37 
models, which often diverge considerably from human phenotype, and clinical trials. 38 
 39 
Methods 40 
Herein, we explore helper-dependent CAV-2 (hd-CAV-2) efficacy and safety for gene 41 
delivery in a human stem cell-derived 3D neural in vitro model. Assessment of hd-42 
CAV-2 transduction was performed at different multiplicities of infection, by evaluating 43 
transgene expression and impact on cell viability, ultrastructural cellular organization 44 
and neuronal gene expression. 45 
 46 
Results 47 
Under optimized conditions, hd-CAV-2 transduction led to stable long-term transgene 48 
expression with minimal toxicity. The evaluation of vector tropism showed that hd-49 
CAV-2 preferentially transduces neurons, in contrast to human adenovirus type 5 50 
(HAdV5) that showed increased tropism towards glial cells.  51 
 52 
Conclusions 53 
This work demonstrates, in a physiologically relevant 3D model, that hd-CAV-2 vectors 54 
are efficient vehicle for gene delivery to human neurons, with stable long-term 55 
transgene expression and minimal cytotoxicity. 56 
 57 
 58 
 59 
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Background 60 
Neurodegenerative diseases, typically characterized by a progressive nervous system 61 
dysfunction, represent a heavy disease burden both in terms of patient suffering and 62 
economic cost. The prevalence of neurologic disorders has dramatically increased over 63 
the last decades and continues to increase, mainly due to higher life expectancy of 64 
populations, which elicits the urgent need for effective therapeutics [1]. 65 
With the increasing knowledge on the etiology of these disorders, several genetic 66 
mutations have been linked with the sporadic and familial forms of disease. The 67 
identification of these mutations can provide not only significant insights in the 68 
molecular mechanisms involved in the disease onset and progression, but also 69 
promising therapeutic targets for alternative approaches to the traditional 70 
pharmacological therapies, such as gene therapy [2]. Briefly, most gene delivery 71 
approaches have focused either on enzyme replacement, by restoring the enzymatic 72 
capacity of the affected brain regions, or on delivery of neurotrophic factors, to prevent 73 
the progression of the neurodegeneration process [3]. 74 
Over the last decades multiple non-viral gene delivery vehicles have been explored, 75 
nevertheless viral vectors are still the most efficient tools for in vivo gene transfer. The 76 
array of viral vector systems offers unique strengths, while presenting specific 77 
drawbacks [4, 5]. Therefore, thorough evaluation is required for selection of the optimal 78 
vector system for central nervous system (CNS) gene delivery. Most neurological 79 
disorders only affect a specific cell type, as is the case of the dopaminergic neurons of 80 
the nigrostriatal pathway in Parkinson’s disease (PD) [6]. Thus, in addition to high 81 
transduction efficiency, vector tropism is of paramount importance to achieve targeted 82 
therapeutic gene delivery to the affected cells of a confined brain region, minimizing 83 
off-target transduction. Additionally, an ideal vector should be able to sustain long-term 84 
expression of the transgene with a single treatment, to maximize the therapeutic effect 85 
and minimize repeated dosage. Most importantly, the vector selection must guarantee 86 
the safety of the patient and avoid host immune responses or cytotoxicity, which may 87 
also hinder the therapeutic effect. Finally, it is important to consider the vector 88 
manufacture methods, which should be scalable and allow high titers along with high 89 
purity and concentration [5, 7, 8]. 90 
Recombinant adeno-associated viruses (AAV) have been the most widely used and 91 
studied vectors for gene delivery in the CNS and peripheral nervous system. The variety 92 
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of AAV identified serotypes enables the mixing of viral genomes and capsids creating 93 
mosaic “pseudotypes” which display a wide range of neural tropisms and efficacies, 94 
along with low pathogenicity and immunogenicity [5, 9]. However, AAV vectors 95 
display a low cloning capacity (≈4-6 kb), which limits their use in some applications. 96 
Recombinant adenoviruses (AdV) are an attractive alternative, due to a large cloning 97 
capacity (8-30 kb) and long-term transgene expression [5, 9], being the most explored 98 
platform in clinical trials worldwide 99 
(http://www.wiley.com/legacy/wileychi/genmed/clinical). Nonetheless, the toxicity and 100 
immunogenicity of some Ad types have been widely described [5, 7, 9], limiting the 101 
therapeutic efficacy. Non human viral vectors, such as canine adenovirus type 2 (CAV-102 
2) derived vectors emerged as an alternative to human rAdV (HAdV), mainly due to 103 
lack of immunological memory [10]. Moreover, CAV-2 vectors preferentially transduce 104 
neurons in the rodent brain and in human organotypic cultures, along with efficient 105 
biodistribution via axonal retrograde transport in neurons [11, 12]. The development of 106 
helper-dependent CAV-2 vectors (hd-CAV-2) [13, 14] improved the efficiency and 107 
duration of transgene expression, minimizing the adaptive cell-mediated immune 108 
response [13]. hd-CAV-2 vectors have a cloning capacity of 30 kb [13] and allow stable 109 
transgene levels over 1 year in immunocompetent rat brain without immunosuppression 110 
[15]. During viral vector development, preclinical testing is crucial to evaluate both 111 
efficacy and safety, while understanding vector-cell interactions. Although the 112 
traditional primary cultures of rodent brain cells and animal models provide valuable 113 
data, these models too often diverge considerably from the human phenotype [16], thus 114 
not accurately predicting the clinical trials’ outcome. In this context, stem cell-derived 115 
human neural cells, along with three dimensional (3D) culture systems, have great 116 
potential as complementary tools in pre-clinical research, bridging the gap between 117 
human clinical studies and animal models [16, 17]. We previously reported the 118 
development of a 3D neural cell model based on the differentiation of human midbrain-119 
derived neural progenitor cells (hmNPC) as neurospheres, in a dynamic culture system 120 
[18, 19]. Differentiated neurospheres contain glial cells, oligodendrocytes and 121 
functional neurons, with enrichment in the dopaminergic phenotype. 122 
In this study, we took advantage of the 3D neural in vitro model [18, 19] to evaluate hd-123 
CAV-2 vectors gene delivery efficiency and cytotoxicity, For this we made use of a 124 
reporter eGFP-expressing hd-CAV-2, which can be produced in a robust and scalable 125 
bioprocess [20, 21], compatible with pre-clinical and clinical applications. Assessment 126 
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of hd-CAV-2 transduction was performed at different MOIs, by evaluation of transgene 127 
expression and toxicity by cell viability, impact on neuronal gene expression and 128 
ultrastructural cell organization. Under optimized conditions hd-CAV-2 transduction led 129 
to stable long-term transgene expression with low toxicity. This study demonstrates, in 130 
a physiologically relevant human in vitro model, that hd-CAV-2 vectors are efficient 131 
vehicle for gene transfer for human neurons and can be envisaged for treatment of 132 
neurodegenerative diseases, such as PD. 133 
 134 
Methods 135 
hmNPC expansion and differentiation 136 
Human midbrain-derived neural progenitor cells (hmNPC) derived from aborted fetal 137 
brain tissue 12 to 14 weeks post-fertilization [18, 22] were kindly provided by Dr. 138 
Johannes Schwarz (Technical University of Munich, Germany). Tissue was obtained 139 
with mother’s consent and in accordance with the Ethics Committee of the University of 140 
Leipzig and the German state and federal laws. Expansion and differentiation of 141 
hmNPC was performed as previously described [18, 19]. 142 
Viral stock production  143 
hd-CAV-2 are vectors derived from CAV-2 strain Toronto A 26/61, GenBank J04368, 144 
containing an eGFP expression cassette. hd-CAV-2 stocks were produced by infection 145 
of E1-complementing dog kidney cells expressing Cre recombinase (DKCre) and 146 
purified by CsCl gradients, as previously described [23, 24]. Stocks titration were 147 
performed by infectivity assay for number of infectious particles/mL (ip/mL) [20, 25]. 148 
The obtained preps had a pp/ip unit ratio of 100:1. HAdV5 vectors used are E1-deleted 149 
adenovirus type 5, expressing green fluorescent protein as transgene (HAdV5-GFP), 150 
which were produced according to previous reports [25]. In this study, multiplicity of 151 
infection (MOI) is determined by the number of infectious viral particles per cell 152 
(ip/cell). 153 
Transduction  154 
Following hmNPC neurospheres differentiation, transduction was performed with 50% 155 
reduction of the working volume. Total cell number was determined by counting cell 156 
nuclei using a Fuchs-Rosenthal hemacytometer after digestion with lysis buffer (0.1 M 157 
citric acid, 1% Triton X-100 (w/w) and 0.1% crystal violet (w/v)) [26]. At 4 hours post-158 
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transduction a complete media exchange was performed. Neurospheres were maintained 159 
in culture up to 30 days post-transduction, with a 75% medium exchange performed 160 
every 3 days. 161 
Cell viability 162 
Cell viability was assessed using the metabolic indicator PrestoBlueTM (Invitrogen), 163 
according to the manufacture’s recommendation. Briefly, neurospheres were plated on 164 
poly-L-ornithine-fibronectin (PLOF)-coated multi-well plates and allowed to attach for 165 
2 hours. Cells were incubated with fresh medium containing 10% (v/v) PrestoBlue, for 166 
2 hours. Supernatant’s fluorescence was measured in 96-well plates using a microwell 167 
plate fluorescence reader (FluoroMax-4, Horiba JobinYvon) and neurospheres were 168 
harvested for total protein quantification, using the Micro BCA Protein Assay Kit 169 
(Pierce). Fluorescence intensity was normalized for total protein and evaluated 170 
relatively to control (MOI 0). 171 
Fluorescence microscopy 172 
Neurospheres were plated on PLOF-coated glass coverslips and allowed to attach for 2 173 
days, fixed in 4% (w/v) paraformaldehyde (PFA) + 4% (w/v) sucrose in PBS for 30 min 174 
and processed for immunostaining as previously described[27]. Primary and secondary 175 
antibodies were used as follows: mouse anti-βIII-tubulin (1:200; Millipore); mouse anti-176 
GFP (1:200; Sigma-Aldrich); rabbit anti-TH (1:100; Santa Cruz); rabbit anti-GFAP 177 
(1:200; Millipore); rabbit anti-CAR (1:200; gift from Joseph Zabner), mouse anti-CAR 178 
(1:200; Millipore); AlexaFluor® 488 goat anti-mouse IgG and AlexaFluor® 594 goat 179 
anti-rabbit IgG (1:500; Invitrogen). Cell nuclei were counterstained with DAPI or TO-180 
PRO-3 (Invitrogen). Samples were visualized using point scan confocal (SP5, Leica) or 181 
multi-photon (Ultima, Prairie) microscopy. Merge between channels and maximum z-182 
projections, as well as linear brightness and contrast adjustments of the images, were 183 
performed using the open source ImageJ software. 184 
Electron microscopy 185 
Neurospheres were fixed in 2.5% (w/v) glutaraldehyde and 4% (w/v) formaldehyde in 186 
0.1 M phosphate buffer (pH 7.4) and then processed for serial blockface scanning 187 
electron microscopy (SBF SEM). Samples were embedded in Durcupan resin following 188 
the method of NCMIR [28]. Small groups of neurospheres were mounted on pins and 189 
trimmed for SBF SEM. Images were acquired using a 3View2XP (Gatan)) attached to a 190 
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Sigma VP SEM (Zeiss), at a resolution of 8,192 x 8,192 pixels (horizontal frame width 191 
of 64.29 µm; pixel size of 7.8 nm) with 2 µs dwell time and 35 nm slice thickness. SEM 192 
was operated in high vacuum, with high current mode active, at an indicated 193 
magnification of 4,000. The 20 µm aperture was used, at an accelerating voltage of 1.4 194 
kV (hd-CAV-2 transduced) or 1.2 kV (control). Alignment of the image stack was 195 
accomplished using the ‘Register virtual stack slices’ plugin in Fiji [29], with translation 196 
based extraction and registration models to minimise distortion of the dataset. Aligned 197 
image stacks were then calibrated for pixel dimensions. Movies were generated using 198 
Amira (FEI Visualization Sciences Group) and Quicktime Pro, showing 500 slices from 199 
the centre of each dataset (total dataset for hd-CAV-2 transduced = 1,450 slices, 200 
representing a total volume of 209,760 µm2; total dataset for control = 533 slices, 201 
representing a total volume of 77,105 µm2). 202 
qRT-PCR 203 
Total RNA was extracted with High Pure RNA Isolation Kit (Roche), according to the 204 
manufacturer’s instructions. RNA was quantified in a NanoDrop 2000c (Thermo 205 
Scientific) and used for cDNA synthesis. Reverse transcription was performed with 206 
High Fidelity cDNA Synthesis Kit (Roche), using Anchored-oligo(dT)18 Primer 207 
(Roche) or with the Super Script III First Strand synthesis system (Invitrogen), using 208 
random hexamers (Invitrogen). qPCRs were performed in triplicates using LightCycler 209 
480 SYBR Green I Master Kit (Roche) with the following primers: eGFP (GFP fwd 5’-210 
CAACAGCCACAACGTCTATATCATG-3’ and GFP rev 5’-211 
ATGTTGTGGCGGATCTTGAAG-3’), tyrosine hydroxylase (TH fwd 5’-212 
AGCCCTACCAAGACCAGACG-3’ and TH rev 5’-GCGTGTACGGGTCGAACTT-213 
3’), synapsin II (SYN2 fwd 5’-TGGAACAGGCAGAATTTTCA-3’ and SYN2 rev 5’-214 
GGACAACCTTTGTGCCATTC-3’) and ribosomal protein L22 (RPL22 fwd 5’-215 
CACGAAGGAGGAGTGACTGG-3’ and RPL22 rev 5’-216 
TGTGGCACACCACTGACATT-3’). As alternative TaqMan Universal PCR Master 217 
Mix (Applied Biosystems), and the following TaqMan® Gene Expression Assays 218 
(Applied Biosystems): TRKA (ID: Hs01021011_m1); TRKB (ID: Hs00178811_m1); 219 
TRKC (ID:Hs00176797_m1); RET (ID:Hs01120030_m1); DDC (ID: Hs01105048_m1); 220 
QDPR (ID: Hs00165610_m1), GCH1 (ID: Hs00609198_m1); DRD2 (ID: 221 
Hs00241436_m1); SYT1 (ID: Hs00194572_m1); SYP (ID: Hs00300531_m1); SYNPO 222 
(ID: Hs00702468_s1); PSD95 (ID: Hs00176354_m1); vGAT (ID: Dm01823909_g1). 223 
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The reactions were performed with Applied Biosystems 7300 Real Time PCR system or 224 
LightCycler 480 Instrument II 96-well block (Roche). Quantification cycle values 225 
(Cq’s) and melting curves were determined using LightCycler 480 Software version 1.5 226 
(Roche). All data were analyzed using the 2-∆∆Ct method for relative gene expression 227 
analysis [30]. Changes in gene expression were normalized using the housekeeping 228 
gene RPL22 (ribosomal protein L22) as internal control. Statistical analysis was carried 229 
out using GraphPad Prism 5 software. 230 
 231 
Results 232 
hd-CAV-2 impact on cell viability and neuronal population 233 
To determine the most suitable transduction parameters, three multiplicities of infection 234 
(MOI) were tested on the human 3D neural model (Figure 1A). We assessed gene 235 
delivery efficiency, by evaluating transgene expression levels, and cytotoxic effects 236 
exerted by the vectors, by measuring cell viability and expression levels of 237 
neuronal/synaptic markers. The different MOIs evaluated (20, 50 and 100 infectious 238 
particles/cell) were selected based on data previously generated with an E1-deleted 239 
CAV-2 vector expressing GFP [18]. Neurosphere transduction showed an increase in 240 
transgene mRNA levels according to the MOI increase, with a 3- and 4.5-fold increase 241 
(relatively to MOI 20) for MOI 50 and 100, respectively, at 5 days post-transduction 242 
(dpt) (Figure 1B). In agreement with these observations, the fraction of GFP-positive 243 
cells also increased with the MOI, as observed by confocal microscopy (Figure 1C).  244 
Cytotoxicity assessment showed no significant decrease in cell viability for MOI 50 and 245 
100, relatively to control (Figure 1D). Moreover, no significant modulation in the pre-246 
synaptic marker synapsin II (SYN2) gene expression was observed for the different 247 
MOIs (Figure 1E). Still, a 4-fold decrease in the expression of the dopaminergic marker 248 
tyrosine hydroxylase (TH) was observed for MOI 100 at 5 dpt, relatively to the 249 
neurospheres before hd-CAV-2 transduction. These results suggest that higher hd-CAV-250 
2 MOIs, although allowing higher gene delivery efficiency, can affect specific neuronal 251 
populations, such as dopaminergic neurons. These observations emphasize the need for 252 
a careful MOI assessment in pre-clinical studies to identify toxic effects, while 253 
sustaining an efficient gene delivery to target cells. In this study, considering the level 254 
of transgene expression and the absence of modulation for the neuronal markers 255 
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evaluated, MOI 20 and 50 were selected for further characterization of hd-CAV-2 256 
transduction. 257 
The impact of hd-CAV-2 transduction on the neurospheres was further addressed by 258 
analyzing the expression of an enlarged set of neuronal markers (Figure 2), comprising 259 
neurotrophic receptors (TrkA, TrkB, TrkC and RET), dopamine biosynthesis pathway 260 
enzymes (DDC, QDPR, GCH1), dopamine receptor (DRD2), pre-synaptic (SYT1, SYP, 261 
SYNPO and vGAT) and post-synaptic (PSD95) proteins. Compared with the control 262 
(MOI 0), a MOI of 20 or 50 for hd-CAV-2 transduction did not induce significant 263 
modulation on the evaluated markers. Thus, given the 3-fold increase in transgene 264 
expression with MOI 50 (Figure 1B) and the comparable low cytotoxic effects, the MOI 265 
50 was selected for more comprehensive studies addressing the impact of hd-CAV-2 266 
transduction on ultrastructural cell organization, vector tropism and duration of 267 
transgene expression. 268 
 269 
hd-CAV-2 impact on ultrastructural cell organization 270 
Cellular ultrastructure was analyzed both for transduced (MOI 50) and non-transduced 271 
neurospheres by serial blockface scanning electron microscopy (SBF SEM). The 272 
obtained image stacks showed similar numbers and spatial distribution of cell bodies, as 273 
well as the complexity of the extending neuronal processes network. Moreover, 274 
comparable cellular ultrastructural details within non-transduced and transduced cells 275 
were observed, including clearly defined mitochondria, Golgi stacks, endoplasmic 276 
reticulum and other subcellular structures. Altogether, these results suggest that hd-277 
CAV-2 transduction did not induced noticeable structural alterations on human neural 278 
cells within the neurospheres. 279 
 280 
hd-CAV-2 tropism and long-term transduction dynamics 281 
hd-CAV-2 preferential transduction of neurons in rodent models has been previously 282 
linked with the expression of coxsackievirus and adenovirus receptor (CAR) [11, 12, 283 
31]. Given this, we analyzed the expression and distribution of CAR on human 284 
neurospheres by confocal microscopy. This revealed that CAR was highly expressed in 285 
neurons, co-localizing with βIII-tubulin-positive cells, but not in glial cells, where low 286 
co-localization with GFAP-positive cells was observed (Figure 4A). To further explore 287 
the interaction between CAV-2 vectors and human neurons, we then incubated 288 
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neurospheres with fluorescently labeled CAV-2 particles (CAV-Cy3), followed by 289 
immunofluorescence labeling of neurons (βIII-tubulin). This resulted in a high density 290 
of CAV-Cy3 particles detected along neuronal cells (Figure 4B), indicating that these 291 
vectors were able to recognize these cells, both in soma and branching processes, for 292 
attachment and internalization. 293 
For a more detailed study on the tropism of hd-CAV-2 in human neural cells, we then 294 
compared the phenotype of hd-CAV-2 transduced cells to a vector derived from human 295 
adenovirus type 5 (HAdV5), which has been widely explored for gene therapy strategies 296 
[32, 33]. Differences both in terms of morphology and distribution of transduced cells 297 
along the neurospheres’ volume were observed (Figure 4C). For hd-CAV-2, the typical 298 
morphology of transduced cells was neuronal-like, with long processes extending from 299 
the soma. By contrast, HAdV5-transduced cells presented glial-like morphology, with 300 
larger cytoplasmic volume and no extension of cell processes. Interestingly, upon hd-301 
CAV-2 transduction, it was possible to identify multiple GFP-positive cells across 302 
different layers towards the inner core of the neurospheres, which was evidenced by a 303 
depth lookup table (Figure 4C). Sections on the surface were plotted in blue progressing 304 
to green and red/pink across a 41 µm volume depth. On the other hand, upon HAdV5 305 
transduction, the presence of GFP-positive cells was restricted to the neurospheres’ 306 
surface, presenting a radial pattern from blue cells in the center towards red/pink cells 307 
only in the periphery. 308 
To confirm the different identity of hd-CAV-2 and HAdV5 transduced cells, different 309 
neural lineages were identified by immunodetection: TH for dopaminergic neurons and 310 
GFAP for glia lineages (Figure 4D). This revealed that hd-CAV-2 were able to 311 
efficiently transduce dopaminergic neurons (TH-positive cells), while poorly 312 
transducing glial cells (GFAP-positive cells), consistent with CAR expression on 313 
neurons. By contrast, HAdV5 preferentially transduced glial cells.  314 
In addition to tropism, we also analyzed the dynamics of transgene expression. 315 
Following hd-CAV-2 or HAdV5 transduction, neurospheres were maintained for at 316 
least 30 dpt, presenting high cell viability. Both vectors were able to sustain the 317 
expression of the transgene during this culture time (Figure 5). hd-CAV-2 maintained 318 
stable eGFP expression levels over the 30 dpt, while HAdV5 transduction led to a 2-319 
fold increase during the first 21 dpt followed by a decrease at 30 dpt to similar levels as 320 
observed at 5 dpt. Moreover, TH expression dynamics revealed no significant 321 
differences between the two vectors during the 30 dpt, suggesting low long-term 322 
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cytotoxic effects of viral transduction on dopaminergic neuronal population for the 323 
selected MOI. 324 
 325 
Discussion 326 
Previous reports on rodents showed the efficiency of CAV-2 vectors in transducing 327 
neurons, with the ability to sustain long-term transgene expression and being 328 
retrogradely transported in neurons, while maintaining low levels of immunogenicity 329 
[12, 15]. Given the fundamental differences between rodent and human cells, it is 330 
critical to demonstrate the efficacy and safety of such vectors in human cells in early 331 
stages of development. In this work, we explored an established human 3D in vitro CNS 332 
model based on differentiation of hmNPC for pre-clinical testing of hd-CAV-2 vectors. 333 
During differentiation, these cells recapitulate the specific midbrain developmental 334 
programs, resulting in a human cell model enriched in functional dopaminergic neurons 335 
[19]. 336 
Here, we found that hd-CAV-2 vectors efficiently transduce human neural cells. The 337 
screening detected cytotoxic effects associated with high vector MOIs (100 ip/cell). 338 
These effects were more evident on the dopaminergic population, as determined by a 339 
significant decrease in TH expression levels and no modulation on synaptic gene SYN2. 340 
Notably, differential hd-CAV-2 transduction efficacy has also been observed in the 341 
rodent brain, where the higher efficiency was observed for dopaminergic neurons, 342 
followed by noradrenergic neurons and the least efficient transduction was observed for 343 
serotonergic neurons (unpublished data). Moreover, dopaminergic neurons have been 344 
previously reported to be more susceptible to GFP toxicity, relative to other neuronal 345 
populations [34]. In this study, transduction of rodent brain with high doses of an 346 
AAV8-GFP vector induced a significant loss in TH+ neurons compared to an empty 347 
vector. By contrast, no loss of pyramidal or granular neurons was observed in the 348 
hippocampus. Together, these data indicate different transduction efficiencies or 349 
transgene related effects in different neuronal subtypes, which can lead to differential 350 
survival. 351 
To confirm the absence of cytotoxicity for the low and mid MOIs (20 and 50 ip/cell), 352 
expression of a larger panel of neuronal genes, including neurotrophic receptors, 353 
dopamine biosynthesis pathway enzymes, dopamine receptors and synaptic proteins 354 
was evaluated at 5 dpt. Here, no significant changes were observed for both MOIs in 355 
12 
 
comparison with the control. These results are in accordance with data on the 356 
toxicogenomic profile of hd-CAV-2 transduction of 2D hmNPC cultures, showing no 357 
significant vector-induced modulation of the neuron morphogenesis pathways and an 358 
activation of pro-survival genes [35]. Moreover, hd-CAV-2 transduction of 359 
neurospheres (MOI 50) did not induce noticeable structural alterations, neither at cells 360 
spatial distribution within neurospheres nor at cellular ultrastructural level.  361 
These results show the importance of MOI screening and optimization to attain efficient 362 
levels of gene delivery, while maintaining cytotoxic effects to a minimal. Nevertheless, 363 
when considering an in vivo setting, one must not exclude possible immunological 364 
complications often associated with a diseased brain and gene transfer vectors, which in 365 
case of AdV are related with innate and memory immunity to the wild-type pathogen. 366 
This can lead to adverse side effects upon administration, such as acute inflammatory 367 
reactions, posing a safety risk for the patient. Still, previous reports have shown 368 
negligible levels of neutralizing CAV-2 antibodies in healthy humans [23], as well as 369 
lower immunogenicity than HAdV in immunologically naïve rodents [15, 36]. As with 370 
all vectors, this should be a matter of careful scrutiny in potential clinical trials to ensure 371 
patient safety and the success of therapy. Moreover, data obtained from rodents may not 372 
accurately reflect the human setting. A recent study showed that HAdV5 and murine 373 
coagulation factor X (FX) complexes stimulated an innate inflammatory response via 374 
Toll-like receptor 4 in murine macrophages [37]. However, HAdV5 and human FX 375 
complexes do not stimulate an innate response in human mononuclear phagocytes [38]. 376 
Our results showed in a 3D human cell model that hd-CAV-2 vectors preferentially 377 
transduce neurons rather than glial cells, in agreement with previous reports on animal 378 
models and ex vivo human brain slices [12, 15]. Transduction with HAdV5 resulted in 379 
preferential glial transduction, further confirming the distinct vector tropism between 380 
CAV-2 and human types. Thus, in spite of sharing many characteristics such as a very 381 
similar capsid structure and genomic organization [39], these vectors display clearly 382 
different tropisms. The molecular basis for CAV-2 neuronal tropism vs. HAdV5 likely 383 
relies on the exclusive binding to CAR for internalization, due to absence of an integrin-384 
interacting motif (e.g. RGD motif), reducing the possibility of vector internalization via 385 
αMβ2 integrins [31]. Hence, CAR expression is essential for CAV-2 transduction, which 386 
in this human model was restricted to the neuronal population, in agreement with 387 
previous reports in rodent models [12]. Thus, our results in a human context further 388 
support the CAR-dependent CAV-2 binding and internalization hypothesis, which leads 389 
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to increased neuronal tropism of CAV-2 and poor glia transduction. Moreover, our 390 
results showed a clear accumulation of CAV-Cy3 particles along neuronal processes, 391 
which indicates that CAV-2 vectors can bind and be internalized along these processes 392 
and not only in the soma. This may also suggest a similar trafficking mechanism as 393 
previously reported for murine primary neurons, where after vector binding to CAR and 394 
subsequent internalization, CAV-2 vectors are transported via axonal trafficking, which 395 
was proposed to be dictated by an innate CAR trafficking mechanism [11, 40].  396 
In addition to CAV-2 tropism, one can further explore strategies for neuronal specific 397 
transgene expression, such as neuronal specific promoters [41, 42], which can reduce 398 
even more potential off target transduction and/or restrict transgene expression to a 399 
neuronal subpopulation (e.g. dopaminergic neurons). 400 
 401 
Conclusions 402 
This work demonstrates, in a physiologically relevant 3D model, that hd-CAV-2 vectors 403 
are efficient vehicles for gene transfer to human neurons, with stable long-term 404 
transgene expression and minimal cytotoxicity. Moreover, in the long term, this study 405 
addresses the potential of hd-CAV-2 vectors for gene therapy of human 406 
neurodegenerative diseases, such as PD, further supporting the valuable data previously 407 
obtained from pre-clinical animal models. 408 
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Figures 554 
Figure 1 - hd-CAV-2 transduction of differentiated human midbrain-derived 555 
neural precursor cells (hmNPC) neurospheres.  556 
(A) Experimental design of cell differentiation and transduction. (B) Fold changes of 557 
eGFP expression for multiplicities of infection (MOI) 20, 50 and 100 infectious 558 
particles per cell (normalized to MOI 20). (C) Confocal microscopy of whole 559 
neurospheres. Maximum intensity z-projections of 38 (MOI 20) and 33 (MOI 50) 560 
optical sections of 1 µm. Scale bars, 100 µm. (D) Cell viability assessment, normalized 561 
for control (MOI 0). (E) Fold changes in tyrosine hydroxylase (TH) and synapsin II 562 
(SYN2) gene expression at 0 and 5 days post-transduction (dpt) (normalized for 0 dpt). 563 
Data are mean ± SEM of 3 independent experiments, asterisks indicate significant 564 
difference (*P < 0.05, **P < 0.01, ***P < 0.001) by a one-way ANOVA analysis with a 565 
Tukey’s post-hoc multiple comparison test. 566 
 567 
Figure 2 - Gene expression analysis of differentiated neurospheres transduced 568 
with hd-CAV-2.  569 
Gene expression fold changes (normalized to control – MOI 0) of neurotrophic 570 
receptors (TrkA, TrkB, TrkC and RET), dopamine biosynthesis pathway enzymes (DDC, 571 
QDPR, GCH1), dopamine receptor (DRD2), pre-synaptic proteins (SYT1, SYP, SYNPO 572 
and vGAT) and post-synaptic protein (PSD95). Data are mean ± SEM of 3 independent 573 
experiments. 574 
 575 
Figure 3 - hd-CAV-2 transduction impact on ultrastructural cell organization of 576 
differentiated neurospheres.  577 
Electron micrographs extracted from the SBF SEM image stacks showing the internal 578 
structure of non-transduced (A) and transduced (B; MOI 50) neurospheres at 5 days 579 
post-transduction. Boxed areas (1, 2) highlight details of ultrastructure within each cell, 580 
including mitochondria (M), Golgi stacks (G), endoplasmic reticulum (ER), and other 581 
subcellular structures (N: nucleus, Np: nuclear pore). Scale bars – 5 µm (a, b), 1 µm (1, 582 
2). 583 
 584 
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Figure 4 - Characterization of hd-CAV-2 and HAdV5 specific tropism.  585 
(A) CAR immunofluorescence confocal microscopy of hd-CAV-2 and HAdV5 transduced 586 
neurospheres. Spatial distribution of transduced cells is highlighted by a depth lookup 587 
table. Maximum intensity z-projections of 41 optical sections of 1 μm, where blue 588 
indicates 0 µm and pink 41 µm. Inset depicts typical morphology of transduced cells. 589 
Scale bars, 50 µm. (B) Immunofluoresce microscopy of neurospheres incubated with 590 
CAV-Cy3 particles (red) stained for βIII-tubulin (green). Nuclei were labelled with TO-591 
PRO3. Single optical section. Scale bar, 20 µm. (C) Immunofluoresce microscopy of 592 
neurospheres transduced with hd-CAV-2 and HAdV5, stained for TH and GFAP. 593 
Maximum intensity z-projections of 55 (TH – hd-CAV-2), 19 (TH – HAdV5), 42 (GFAP – 594 
hd-CAV-2) and 23 (GFAP – HAdV5) optical sections of 0.33 μm. Scale bars, 50 µm. (D) 595 
Immunofluoresce microscopy of neurospheres stained for CAR, βIII-tubulin and GFAP. 596 
Maximum intensity z-projections of 33 (βIII-tubulin) and 14 (GFAP) optical sections of 597 
0.38 μm. Scale bars, 20 µm. 598 
 599 
Figure 5 - hd-CAV-2 and HAdV5 transgene expression dynamics.  600 
Gene expression fold changes of eGFP (A) and TH (B) expression in hd-CAV-2 and 601 
HAdV5 transduced neurospheres, along 30 dpt. Data are mean ± SEM of 2 602 
independent experiments. 603 
 604 
Additional files 605 
Video S1 – Serial block-face scanning electron microscopy (SBFSEM) image stack 606 
of non-transduced neurospheres. The video scrolls through Z, X, and Y axes, 607 
respectively. 608 
 609 
Video S2 – Serial block-face scanning electron microscopy (SBFSEM) image stack 610 
of transduced neurospheres (MOI 50). The video scrolls through Z, X, and Y axes, 611 
respectively. 612 
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